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The opsonic action of human serum from cases of pneumonia has 
been studied very thoroughly by Sia, Robertson and Woo (1), using 
their own technique.  They found that the opsonic titre of the serum 
rose rapidly during and just after the crisis of the disease, and slowly 
decreased in the weeks that followed.  This was so regular an occur- 
rence that they were naturally inclined to believe that the crisis was 
the result of this rise.  Other authors have noted that the crisis  is 
contemporaneous with the appearance of mouse-protective substances 
in the serum.  Indeed, in most of the work that has been done on the 
serum in pneumonia, attention has been focussed on these very striking 
changes that occur about the period of crisis, and which are almost 
certainly causally connected  with that phenomenon. 
The present study is not concerned with the direct phagocytic action 
of the blood of individuals suffering from pneumonia, for the blood 
in the early stages of pneumonia appears to act in this respect like the 
blood of healthy individuals (see Paper I), and as has been mentioned 
above, the blood at crisis has already been studied by Sia, Robertson 
and Woo.  It is an attempt, however crude, to reproduce in the test 
tube the struggle that must go on in the lungs in serum-treated cases 
between the pneumococcus and its products on the one hand, and the 
blood and antiserum on the other.  Admittedly, the reproduction is in- 
complete, because---owing to experimental limitations--one must leave 
out the tissue cells altogether, but at least it is possible to study the 
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interplay of the above factors on one another.  If one studies under 
the microscope two  opsonic preparations,  one with  normal  human 
blood and virulent pneumococci, and the other with normal human 
blood and non-virulent pneumococci, a very different picture is seen. 
In the former case, the leucocytes are almost all empty, in the latter 
case, they are filled with pneumococci.  If specific antiserum is added 
to the former preparation, the leucocyctes now take up the organisms 
readily.  We know that the virulent organisms are capsulated and 
contain the specific soluble substance, and that the non-virulent organ- 
isms are not capsulated and contain no specific soluble substance.  We 
know, further, that the specific soluble substance has a specific anti- 
phagocytic effect--see Paper I.  It would appear probable, then--as 
Dr. J. M. Alston suggested to the author--that the so-called "sensitiz- 
ing" action of a specific antiserum is really a "neutralizing" action, the 
substance neutralized being the capsule composed largely of specific 
soluble  substance.  When  this  substance  is  neutralized,  the  cap- 
sulated, virulent pneumococcus behaves like a  non-capsulated, non- 
virulent pneumococcus  and is easily phagocyted.  It was demonstrated 
many years ago by Dochez and Avery (2)  that the specific soluble 
substance of the  pneumococcus could be  detected in  the  urine  in 
cases of pneumonia during the  course of the disease.  Presumably 
this substance is set free in the lesion itself and it is reasonable to 
assume that if it can be detected in the urine, it must be present in still 
greater concentration in the lungs, though what the actual concentra- 
tion there may be is not known.  Granting this assumption, the strug- 
gle in the lungs in serum-treated cases would seem to narrow down to 
one between the antiserum on the one hand, and the specific soluble 
substance (both free and in the capsules of the living pneumococci) 
on the other, with the phagocytes as the arbiters of the outcome.  It 
would be natural to suppose that if, after the free specific soluble sub- 
stance had been neutralized by the antiserum, there was enough free 
antiserum remaining to neutralize the specific soluble substance in the 
capsules of the living pneumococci, these would be  phagocyted, and 
the patient speedily recover; but that if the specific soluble substance 
remained in excess,  there would be no free antiserum to "sensitize" 
the pneumococci, which would therefore not be phagocyted, and the 
patient's life would be endangered.  On this supposition, the problem HUGH K.  WARD  687 
of serum therapy would resolve itself simply into giving enough anti- 
serum to neutralize the specific soluble substance; in other words, giving 
as much as possible, as often as possible, of a serum which is as strong 
as possible.  And that is the usual practice in modern serum therapy 
in pneumonia. 
The following experiments indicate, however, that very little anti- 
serum is necessary to neutralize comparatively strong concentrations 
of specific soluble substance, and that if that amount of antiserum is 
exceeded, phagocytosis is  inhibited. 
In  Paper  I,  it was  shown--using  Todd's technique  that  normal 
human whole blood was able to phagocyte very considerable numbers 
of virulent  pneumococcl,  and  that  the  specific carbohydrate  had  a 
specific antiphagocytic  action  on  the  blood,  much  more marked  in 
the case of Type HI than with Type I.  An attempt was now made to 
study the neutralizing power of the specific antiserum on the specific 
carbohydrate,  using  phagocytosis  of  the  type  organism  by  whole 
blood as the indicator of whether the carbohydrate had been neutral- 
ized  or  not.  The  Type III  system  was  first  studied,  and--to  the 
author--quite  surprising  results were obtained. 
A number of tubes were filled with 0.5 cc. of defibrinated human blood.  Two 
drops of a 1/10,000 concentration of Type III specific soluble substance in normal 
saline were added to all the tubes (except the control series).  The tubes were then 
divided into sets of six, and in each set, one drop of Type Ill horse antiserum of a 
certain dilution was added to each of the six tubes.  The dilutions of the serum 
were made in normal saline solution and the following dilutions were commonly 
employed: (1) undiluted serum; (2) 1/4; (3) 1/15; (4) 1/54; (5) 1/255; (6) 1/1000; 
(7) 1/4000;  (8)  1/15,000;  (9)  1/54,000;  (10) no serum.  To these ten series was 
added a control series of six tubes, containing neither specific soluble substance nor 
serum, in order to show the normal phagocytic titre of the blood.  To the first tube 
in each of these eleven series was then added one drop of a 1/10 dilution in broth 
of an 18-hour culture of Type III pneumococcns in rabbit blood hormone broth. 
To the second tube in each series a drop of a 1/100 dilution of the culture, and so 
on.  The tubes were then sealed and incubated over night in the rotating apparatus. 
The next day the tubes were opened and a loopful of the contents streaked on 
blood agar plates.  The plates were incubated for 24 hours, and the amount of 
growth from the streaks was roughly estimated.  The result is set out in Table I. 
It shows the estimated concentration of both the specific soluble substance and the 
antiserum in the blood, and the estimated number of diplococci which were added 
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This experiment was repeated vcith the blood of another individual 
with a lower phagocytic titre, and also with a  1/750,000 concentration 
of specific soluble substance.  There were slight variations from Table I, 
but  there  was  the  same  general  picture.  Table  I  shows at a glance 
that it is not simply an excess of antiserum which determines the most 
efficient phagocytosis.  For example, in Series I, it can easily be shown 
that the antiserum is in excess.  If the blood is replaced by saline, and 
the precipitate  formed by the specific soluble substance and the anti- 
TABLE  I 
Type HI 
Series 
I  II  IU  IV  1 V [ VI  } VII  I VIII I  IX  X  XI 
Concentration of spec. sol sub. 
Concentration of antiserum 
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serum is centrifuged down, the addition of more specific soluble sub- 
stance to the supernatant fluid results in another precipitate forming, 
showing there was an excess of antiserum in the original mixture.  In 
the eighth and ninth series, where the specific soluble substance is in 
excess, the phagocytosis is again inefficient, as was to be expected, for 
the tenth series shows the powerful antiphagocytic  action of  specific 
soluble substance on the normal phagocytic power of the blood, shown 
in the eleventh series.  In between the series where the antiserum is in HUGH  K.  WARD  689 
marked excess and the series where the specific soluble substance is in 
excess is a zone--series V, VI and VII-- where phagocytosis is efficient. 
Here, in all probability, the antiserum is in slight excess, or there is a 
neutral mixture of specific soluble substance and antiserum. 
A  similar  experiment  was  then  carried  out  with  Type  I  specific 
soluble substance and Type I antiserum, and no pro-zone of inefficient 
phagocytosis was found, so that it was thought  at first that the phe- 
nomenon  shown with Type III did not occur in the case of Type  I. 
TABLE  II 
Type I 
Series 
I  II  HI  IV  ]  V  [  VI  I  VI  VIII  IX  X  XI 
Concentration of spec. sol. sub. 
diplococci  ~  " 
inoculated  ~  ~.  ~ 
Concentration  of antiserum 
TM 
250,000  ::÷ 
25,000 
2,500  ++ 
250 
25  + 
2  0 
+.  ÷ 
÷  + 
+  -+ 
--  M 
~-~ 
+ 
++ 
0 
0 
0 
0 
0 
However, the Type I antiserum used on this occasion was a weak one, 
and later a  very much stronger antiserum  was  obtained,  containing 
about 2000 units.  With this antiserum a Type I  experiment was set 
up similar in every way to the Type III experiment.  The antiserum 
used in all these experiments, whether Type I  or Type III,  was the 
natural serum not concentrated. 
The result of the Type I experiment, using the strong antiserum, is 
shown in Table II.  Here, with Type I, is seen the same phenomenon 690  PHAGOCYTOSIS  OF  PNEUMOCOCCUS.  II 
that was demonstrated with Type III, but very much less marked, so 
that it is evidently common to all the strains of pneumococcus, varying 
only in degree.  No Type II specific soluble substance was available, 
so that a Type II experiment could not be carried out,  but from what 
we know of Type II, it is likely that it would give a result intermediate 
between Type I  and Type III. 
Since it might be argued that the addition to the tubes of specific 
soluble substance--a highly purified product of pneumococcus metab- 
olism-is  a  somewhat artificial  procedure,  and  that  the  unpurified 
product might have a different action, an experiment was carried out, 
using  the  undiluted  filtrate  of a  20  hour  broth  culture  of  Type  I 
pneumococcus, instead of the specific soluble substance.  The result 
was in every way similar to that shown in Table II. 
An attempt has been made to find an explanation of why there is 
interference with phagocytosis in the series with considerable excess of 
antiserum.  It is well known that in the precipitin reaction, if the anti- 
serum is in sufficient excess, the precipitate formed is dissolved in the 
antiserum,  the so-called "pro-zone" or inhibition zone.  But the pre- 
cipitin inhibition zone has only a very indirect bearing on the phenom- 
enon  described above, which  might be called  the  phagocytic  inhibi- 
tion zone.  If the blood in the various series is replaced with saline, one 
can observe the precipitates  formed in each  series.  There is a  pre- 
cipitate visible in the first series, diminishing in amount as the serum is 
diluted in  the later series.  This in itself pointed to  the precipitate 
being the interfering factor, so a simple experiment was set up. 
Specific soluble substance  and  antiserum--both  Type  III--were  mixed in 
suitable concentration so that a heavy precipitate formed.  The precipitate was 
centrifuged down and the clear supernatant  fluid pipetted off.  The precipitate 
was washed three times in saline solution and then re-suspended in saline.  Three 
series of tubes were set up with 0.5 cc. of whole blood in each tube.  To the first 
series, one drop of saline was added; to the second series one drop of re-suspended 
washed precipitate, and to the third series one drop of the supernataut fluid.  Each 
series was then inoculated with Type III culture in the usual way.  The tubes 
were sealed, incubated in the rotating apparatus and streaked out on the following 
day.  Table III shows the result. 
This  experiment  brings out very clearly that  it is the  precipitate 
which interferes with phagocytosis,  and  that  the  clear  supernatant HUGH  K.  WARD  691 
fluid of  the  antiserum-specific carbohydrate  mixture  reinforces the 
natural phagocytic power of the blood. 
The next question of course that arises is: Where does the precipi- 
tate act?  Does it interfere with the leucocytes themselves, or does it 
exert its inhibiting action in some way on the serum, perhaps adsorb- 
ing some substance from the serum which is necessary for phagocyto- 
sis?  With regard to the latter possibility, it is not inconceivable that 
phagocytosis would be more  effective in  the presence than in  the 
absence of complement, and it is known that complement is usually 
adsorbed by specific precipitates.  Would the adsorption of comple- 
ment by the specific precipitate explain, then, the inefficient phago- 
cytosis?  This possibility was investigated by incubating for 2 hours a 
tube containing the uninoculated mixture in Series I of Table I  (con- 
TABLE  III 
Number of diplo¢occi  Blood +  saline  Blood + washed preclpi-  Blood  +suj~ernatant 
inoculated  tste  nuta 
700,000 
70,000 
7,000 
700 
70 
7 
++++ 
+++ 
+ 
0 
0 
o 
++ 
++ 
+++ 
+++ 
+++ 
+ 
+ 
o 
o 
0 
o 
o 
sisting of blood, Type III antiserum and Type III specific carbohy- 
drate) and also a tube containing the uninoculated Series XI of Table I 
(consisting of blood only).  The serum was then pipetted off both 
tubes and tested for complementing power with sensitized red cells. 
It was found that the complementing power of the serum, where the 
precipitate was present, had fallen to half that of the control tube, but 
that there was still a large amount of complement remaining.  That 
more complement was not adsorbed by the precipitate appears sur- 
prising, but this result is characteristic of the pneumococcus antigen- 
antibody complex, where horse serum is the source of the antibody, as 
Zinsser and Parker (3) have shown, using guinea pig complement. 
That the precipitate does not exert its action  on  the  serum can 
be shown in another way, by the following experiment: 692  PHAGOCYTOSIS  Ol  ~ PNE~OCOCCUS.  II 
An equal amount of human whole blood was placed into two centrifuge tubes. 
The tubes were centrifuged,  and the serum pipetted off and kept separate.  The 
corpuscles in each tube were washed three times in saline solution.  The serum 
from Tube 1 was then replaced on the washed corpuscles of  Tube i.  Washed 
antiserum-specific  carbohydrate precipitate was  then added to the serum from 
Tube 2, which was incubated for an hour.  The precipitate was then centrifuged 
down, and the supernatant serum replaced on the washed corpuscles  of Tube 2. 
There were thus two mixtures, one consisting  of washed corpuscles  and normal 
serum,  the other consisting  of washed  corpuscles and serum which had been in 
contact with the precipitate for an hour at 37°C.  A series of six tubes, each con- 
taining 0.5 cc. of the first mixture, was set up, similarly, a series of six tubes with 
the second mixture.  Each series was inoculated with decreasing numbers of organ- 
isms in the usual way, the tubes were sealed, incubated in the rotating apparatus, 
and then plated out on the following day.  Table IV shows the result of this 
experiment. 
TABLE  IV 
Number of dlplococci inoculated  Washed corpuscles  +  normal  Washed corpuscles +  predpit~te- 
serum  treated serum 
700,000 
70,000 
7,000 
700 
70 
7 
++++ 
+++ 
++ 
0 
0 
0 
++++ 
+++ 
+ 
0 
0 
0 
Thus it is seen that the precipitate does not appear to act on the 
serum in any way.  By this process of exclusion, one is forced to con- 
clude that the precipitate acts on the leucocyctes themselves. 
It is not definitely known how the precipitate prevents the leuco- 
cytes from effectively phagocyting  the  sensitized  pneumococci,  but 
Cromwell and Centeno in a recent paper (4) have described the vacuo- 
lation of leucocytes when incubated with specific precipitates.  These 
authors  are of  the  opinion  that  the  vacuolation is  associated  with 
digestion  of  the  precipitate.  Therefore,  it  may  well  be  that  such 
vacuolated leucocytes, while digesting the precipitate, are incapable of 
taking up sensitized pneumococci in the normal manner. 
If the phagocytic function of the leucocytes is impaired by the diges- 
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with bacterial phagocytosis is non-specific.  That, for example, a Type 
III precipitate would interfere with the phagocytosis of the other types 
of pneumococci, as well as with Type III.  That this is the case is 
shown by the following experiment, in which washed Type III precipi- 
tate was added to a series of tubes containing 0.5 cc. of blood, while an 
equal amount of saline solution was added to another series of tubes 
containing the same amount of blood.  Each series was then inocu- 
lated with decreasing numbers of Type I organisms, the tubes sealed, 
incubated on  the  rotary  apparatus,  and plated out  the  next  day. 
(See Table V.)  The control blood in this experiment did not have a 
high phagocytic titre against Type I organisms, but in the presence of 
Type III precipitate, it had no titre at all against Type I pneumococci. 
Up  to  this  point,  these  phagocytic zones  have  been  studied  in 
TABLE  V 
Number of Type I diplococci 
inoculated 
600,000 
~,~0 
6,000 
~0 
60 
6 
Blood + Type  III precipitate 
++++ 
++++ 
++++ 
++++ 
++++ 
++++ 
Blood + saline 
++++ 
++++ 
+++ 
o 
o 
o 
relation  to  variations of the  antiserum concentration, keeping  the 
concentration of specific carbohydrate constant.  But in  the lungs, 
we have no knowledge of what the concentration of this substance 
may be.  It can be shown that the zone of efficient phagocytosis moves 
slightly to  the left if the  concentration of specific carbohydrate is 
raised above that shown in Tables I  and II, and that it moves slightly 
to the right if the concentration is lowered.  It is probable that these 
shifts are bound up with the amount of precipitate formed with differ- 
ent concentrations of specific carbohydrate. 
Although the experiments shown in Tables I and II are necessary to 
establish the phagocytic relationships between blood, specific soluble 
substance, antiserum and pneumococci, they are obviously much too 
extensive to carry out on every specimen of antiserum to ascertain the 694  PHAGOCYTOSIS  OF  PNEU~OCOCCUS.  II 
optimum dilutions for in vitro phagocytosis.  An endeavor was there- 
fore made to cut such experiments down to  a  more reasonable size, 
without at the same time losing any essential information about the 
antiserum.  This can be done satisfactorily by setting up a  series oI 
tubes containing a  constant amount of blood, a  constant amount of 
specific soluble substance,  a  constant number of pneumococci, and a 
varying amount of the antiserum to be tested.  The following are the 
details of a Type I experiment set up in this way: 
A series of tubes was filled with 0.5 cc. of blood; two drops of a 1/I0,000 concen- 
tration of Type I specific soluble substance were added to each tube, giving a final 
concentration of about 1/75,000 of this substance; one drop of a 1/10 dilution of an 
18 hour culture of Type I pneumococcus in rabbit blood hormone broth was also 
added to each tube (in the actual experiment shown in Table VI, the drop con- 
tained approximately 300,000 diplococci); and finally, a drop of serum was added 
to each tube, undiluted in the first tube, diluted 1/2 in the second tube, diluted 1/4 
in the third tube and so on, giving final concentrations of the serum in the tubes as 
follows: 1/20 in the first tube, 1/40 in the second tube, 1/80 in the third tube, and 
so on.  The tubes were sealed, incubated in the rotating machine and plated out 
the next day.  In this experiment, the results of which are shown in Table VI, 
three different antiserums were titrated in this way on two different specimens of 
human whole blood.  Antiserum X was an unconcentrated serum containing 2000 
units, Antiserum Y was a Felton concentrated serum containing 4500 units, Anti- 
serum Z was a Felton concentrated serum containing 3500 units. 
In general, these three antisera show the same end-point, except that 
Antiserum Z  appears  slightly stronger than the others with Blood A. 
But the two concentrated antisera have a  definitely longer inhibition 
zone than the unconcentrated serum.  This experiment shows approx- 
imately the maximum phagocytic action of the antiserum under  these 
conditions; so that the zone of efficient phagocytosis is a  comparatively 
narrow one.  If fewer organisms were added to the tubes,  this zone 
would of course be wider. 
It would not be difficult to standardize  antisera  by this  method, 
the standard antiserum being always set up under the same  conditions 
as the unknown antisera, but until more is known of the  significance 
of the phagocytic titre of an antiserum, a  discussion of whether such 
a method is to be preferred to the mouse protection method would be 
premature.  Theoretically, there are objections to both methods as a 
measure  of  the  therapeutic  value  of  an  antiserum,  and  Goodner's HUGH ~.  WAlU~  695 
therapeutic method (5) of testing antiserum on infected rabbits would 
be the method of choice if one could be quite confident that the lung 
lesion in a human being reacted to antiserum like the skin lesion in a 
rabbit. 
It is hardly necessary to  say that if it could be  shown that the 
in vitro phagocytic inhibition zone could be paralleled in vivo by a pro- 
tection inhibition zone, the test-tube experiments would have practical 
importance, and could not be considered as of theoretical interest only. 
Protection inhibition zones in mice have been described by  Felton 
TABLE  VI 
Blood A  Blood B 
Concentration of 
antiserum 
1/20 
1/40 
1/80 
1/160 
1/320 
1/640 
1/1,280 
1/2,500 
1/S,O00 
l/t0,000 
1/20,000 
1/40,000 
1/80,000 
Antiserum X 
++++ 
++++ 
++++ 
+++ 
+ 
o 
o 
o 
o 
o 
++++ 
++++ 
++++ 
M~mm  Y 
++++ 
++++ 
++++ 
++++ 
+++ 
+++ 
0 
0 
0 
0 
+++ 
++++ 
++++ 
A~fisemra Z 
++++ 
++++ 
++++ 
+++ 
+++ 
+++ 
o 
o 
o 
o 
o 
++++ 
++++ 
Antiserum X 
++++ 
++++ 
++++ 
+++ 
+ 
o 
o 
o 
o 
o 
+ 
++++ 
++++ 
Antiserum Y 
++++ 
++++ 
++++ 
++++ 
+++ 
+++ 
+ 
o 
o 
o 
+ 
++++ 
++++ 
Antiserum  Z 
++++ 
++++ 
++++ 
++++ 
+++ 
+++ 
o 
o 
o 
o 
+ 
++++ 
and Bailey (6) and by Sobotka and Friedlander (7).  It has not been 
possible to demonstrate a protection inhibition zone in Type I experi- 
ments on mice, using 0.2  cc. of undiluted 2000 unit antiserum as the 
maximum dose of serum.  In the case of Type  III,  however,  more 
success was obtained, as the following experiment shows: 
Forty-two mice were divided into seven groups of six mice each.  All the mice 
received an injection of 0.2 cc. of a 1/10,000 concentration of Type III specific 
soluble substance.  Group I received 0.2 cc.  of undiluted Type III antiserum; 
Group II 0.2 cc. of a 1/4 dilution of the antiserum; Group III 0.2 cc. of a 1/16 dilu- 
tion; Group IV 0.2 cc. of a 1/64 dilution; Group V 0.2 cc. of a 1/256 dilution; 
Group VI 0.2 cc. of a 1/1000 dilution; Group VII 0.2 cc. of a 1/4000 dilution. 696  PHAGOCYTOSIS  OF  PNEUMOCOCCUS.  II 
One mouse in each group was then injected with 0.5 cc. of a 1/5 dilution in broth  of 
an 18 hour broth culture of Type III pneumococcus--the minimal lethal dose of the 
culture being 0.000,000,1  cc.; one mouse in each group was injected with 0.5 cc. of a 
1/500 dilution of culture, and so on, so that the sixth mouse in each group received 
0.5 cc. of a  1/500,000  dilution of the culture.  Table VII shows  which mice had 
died and which survived at the end of 96 hours. 
Owing doubtless to the difference in resistance between one mouse 
and another, the result of this in vivo experiment is not as consistent as 
the parallel in vitro experiment shown in Table I, but the general picture 
is clear enough--a well-marked protection inhibition  zone with  undi- 
TABLE  VII 
0.2 Cc. of 1/10,000  Concentration of Specific Soluble Substance 
Dilution of 
culture 
~/s 
1/so 
1/soo 
1/5,000 
1/so,ooo 
1/soo,ooo 
0.2 cc. of 
undiluted 
antiserum 
D 
D 
S 
D 
D 
S 
0.2 cc. of 
1/4 dilution 
antiserum 
D 
D 
S 
D 
S 
D 
0.2 cc. of 
1/16 dilution 
antiserum 
D 
D 
S 
D 
D 
S 
l?d  :" of  ,  [ution 
anti  rum 
I 
0.2cc, 0f  I  0.2o 
1/256  I  1/1; 
dilution  I  dilut 
antiserum  antis¢ 
S  1~ 
S  E 
S  13 
S  S 
S  S 
,b~  f 
ion 
:um 
0.2 cc. of 
114,000 
dilution 
antiserum 
D 
D 
D 
D 
D 
S 
S  =  survival. 
D  =  death. 
luted  serum,  with  serum  diluted 1/4 and  1/16;  a  zone  of  efficient 
protection with  serum diluted 1/64 and 1/256; followed by a zone of 
ineffective protection when the serum was diluted too highly.  The 
experiment is sufficiently clean cut.  It suggests that if the injection of 
Type III specific soluble substance into a mouse at the same time that 
it is infected with Type III pneumococci parallels the case of a human 
being suffering from Type III pneumonia, then a comparatively small 
dose of Type III antiserum is all that is necessary to effect a  cure, 
while more than that amount of serum would be harmful. 
If it were possible to find an animal which reacted with a  localized 
lesion to pneumococcus infection, and whose blood reacted similarly 
to human blood, it would be possible to carry out controlled therapeu- HUGH  K.  WARD  697 
tic experiments with different amounts of antiserum, based on the in 
vitro  measurements.  In  the  attempts  that  have  been made,  rabbit 
blood has not reacted like human blood in the presence of antiserum, 
specific soluble substance and pneumococci. 
An  opportunity  arose,  however,  through  the  courtesy of Doctors 
Sutliff and Finland of the Boston City Hospital, to test the blood of a 
case of Type I  pneumonia which was being treated with large doses of 
strong antiserum. 
A specimen of blood was taken from the patient after 28 cc. of antiserum had 
been administered,  and again 14 hours later, after 180 cc. of antiserum had been 
given in all.  On the theory that the r61e of the antiserum is to neutralize the 
specific soluble substance in the lung,  each specimen  of blood was divided into 
TABLE  VIII 
I 
Blood after 28 ce. of antiserum  [  Blood after 180 ce. of antiserum 
[ 
Number of 
dlplococci  Concentration of sI~e. sol. sub. 
inoculated 
1/1,690 
350,000  ~- 
35,000  0 
3,500  0 
350  0 
35  0 
3  0 
1/1~  ~0 
4 
1/160,000  0 
+  o 
o  o 
o  o 
o  o 
o  o 
o  o 
I/1,60___~0 
++ 
? 
o 
1/16,000 
++o + 
1/160,000 
+++ 
+++ 
+++ 
+++ 
++o + 
0 
0 
0 
0 
0 
0 
parts; one part was kept as a control and a varying amount of the specific carbo- 
hydrate was added to each of the other parts.  All were then tested in the usual 
way by infecting with Type I pneumococci, incubating,  and plating out.  Table 
VIII shows the result of this experiment. 
The  table  shows  at  a  glance  that  phagocytosis  is  far  more 
effective under  these  conditions after a  dose  of 28  cc.  of  antiserum 
than  after 180 cc., no matter what  concentration  of specific soluble 
substance is present.  A  simple calculation, based on a  blood volume 
of 5000 cc., shows that a  dose of 28 cc. of antiserum results in  a  con- 
centration of  1/180  of antiserum  in the patient's  blood,  and  that  a 
dose of 180 cc. of antiserum results in a  concentration of 1/28 of anti- 
serum.  Reference to  Table  II  shows  that  with  a  concentration  of 698  PHAGOCYTOSIS  OF PNEUMOCOCCUS.  II 
1/180 of antiserum, phagocytosis is fairly good, while with a concen- 
tration of 1/28 of antiserum, phagocytosis is very markedly inhibited. 
So the results obtained by the in vitro addition of the antiserum (shown 
in Table II) parallel fairly well the results with the in  vivo  injection 
of  the  antiserum  (shown in Table viii).  To obtain the optimum 
phagocytic effect in the presence of specific soluble substance, probably 
the injection of only 10 cc. of the antiserum would have been sufficient 
in the above case.  It is significant that 2 hours after 28 cc. of anti- 
serum had been administered, there were still pneumococci in  this 
patient's blood stream, probably thrown off from the lesion, because it 
will be seen from the table that the blood alone was strongly phago- 
cytic.  But after 180 cc. of serum had been given, the blood stream 
was sterile, and the patient's general condition improved.  This im- 
provement was maintained and recovery was uninterrupted.  In other 
words,  a  dose of antiserum which was fairly efficient in promoting 
phagocytosis in the presence of  the specific  carbohydrate led to no 
apparent clinical improvement, whereas a much larger dose of anti- 
serum which resulted in little or no phagocytosis in the presence of the 
carbohydrate, led to apparently marked clinical improvement. 
A Type III antiserum was titrated out for its opsonic power in the 
presence of Type III specific soluble substance.  It was a  weak serum 
and showed its optimum phagocytic effect in a  concentration of 1/80. 
To attain this concentration in the blood of an adult, about  60 cc. 
would have to be given.  This dose was injected, but had no apparent 
apparent clinical effect whatever on the Type III cases in which it was 
tried. 
DISCUSSION 
It is well-known that in ~itro phagocytosis of virulent pneumococci 
by human blood is aided by the addition of antiserum alone; Sia's 
work has been confirmed that phagocytosis is hindered by the addition 
of specific carbohydrate alone; and it has been demonstrated in these 
experiments that when both antiserum and specific carbohydrate are 
present, phagocytosis may be inefficient if there is too much antiserum 
as well as too little antiserum.  There is, however, an optimum con- 
centration of antiserum which will neutralize the specific carbohydrate 
and aid phagocytosis.  This optimum concentration differs in different 
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The inhibition of phagocytosis, when strong  antiserum is used to 
neutralize the specific carbohydrate is probably caused by the specific 
precipitate formed interfering, perhaps mechanically, with the inges- 
tion of the pneumococci by the leucocytes.  The phagocytic inhibition 
zone is better marked with Type III pneumococcus than with Type I, 
probably because the Type III precipitate is much heavier than the 
Type  I  precipitate.  That  the  interference  with  phagocytosis  by 
precipitates is a  general phenomenon is borne out by the work of 
Todd (8),  who has described the inhibiting action of precipitates in 
the phagocytosis of staphylococci and streptococci. 
It is an open question what bearing these results have on what occurs 
in the lungs in cases of pneumonia specifically treated with antiserum. 
For some years now it has been generally thought that the r61e of the 
antiserum is not simply one of sensitizing the invading pneumococci to 
phagocytosis.  Patients suffering from pneumonia were found often 
times to have in the urine a substance which reacted specifically with 
the antiserum--the "specific soluble substance" of Dochez and Avery, 
the "residue antigen" of Zinsser.  Since that time, the antiserum has 
been assigned at least two functions, firstly of neutralizing the specific 
soluble substance, and secondly  of sensitizing the pneumococci.  It was 
further believed, quite logically, that if the specific soluble substance 
remained in excess, the pneumococci would not be sensitized, because 
the same antibody in the antiserum was concerned in neutralization 
of the specific soluble substance and the sensitization of the pneumo- 
cocci.  In other words, this theory demanded that there had to be 
enough of this antibody remaining in excess after the specific soluble 
substance  had been neutralized, to sensitize the organisms.  Success 
in specific therapy therefore  depended on giving enough antiserum 
to more than neutralize the specific  soluble substance, and the large 
doses of antiserum that were apparently necessary were accounted for 
by the difficulty of this neutralization, and in the case of Type III 
pneumonia, this was almost if not quite impossible with the antisera 
available. 
In the experiments described in this paper,  an attempt has been 
made to study the quantitative relationship between antiserum, specific 
soluble substance and living pneumococci by a phagocytic technique 
in test-tubes, using human whole blood.  It has been found that in 700  PHAGOCYTOSIS  OF PNE~0COCCUS.  II 
this  comparatively simple phagocytic system,  a  surprisingly small 
concentration  of  therapeutic  antiserum  is  sufficient  to  neutralize 
moderately  strong concentrations of specific soluble substance and still 
leave enough antiserum in excess to sensitize the pneumococci.  And 
further that if the concentration of the antiserum rose to the concen- 
tration generally used in therapy, an inhibition zone very markedly 
reduced  the  amount  of  phagocytosis.  Despite  the  disappointing 
results of Type IIi therapy, it was found to be just as easy to neutral- 
ize the Type III specific soluble substance as it was the Type I  sub- 
stance.  Naturally  the  first  deduction made in  the  light  of  these 
experiments was that the dose of antiserum in treating pneumonia was 
far too large.  This theory was put to the test and found to be erro- 
neous.  In an actual case of Type I pneumonia treated with antiserum 
in which the blood was tested at two stages during the treatment, it 
was found that after a fairly small dose of antiserum, the phagocytic 
titre of the blood in the presence oI the specific carbohydrate  was good, 
but no clinical effect could be observed, the blood culture remaining 
positive; whereas after a fairly large dose of serum had been adminis- 
tered, the phagocytic titre of the blood had almost vanished in the 
presence of the  carbohydrate, but  the clinical  effect was a  definite 
improvement, which was subsequently sustained.  Further, a dose of 
Type III antiserum, calculated to effectively  neutralize the Type III 
specific soluble substance and promote optimum phagocytosis, had no 
clinical  effect whatever when injected into cases of Type III pneu- 
monia. 
What then is  the explanation of this contradiction?  No definite 
answer can be given at the present time, but there are several expla- 
nations possible. 
It might be said that one cannot argue from an  artificial  and ad- 
mittedly incomplete combination of reacting substances in test-tubes 
to the actual processes in the lesion.  While it is true that one cannot 
argue definitely from one to  the other, this  test-tube method, how- 
ever imperfect, is perhaps the most direct approach available towards 
the understanding of the protective mechanism in pneumonia.  The 
results, though not conclusive,  may well be suggestive, even if they 
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It might be said that--granted that only a minimal amount of anti- 
serum is necessary to  neutralize the specific soluble substance--the 
circulation in the lesion is so poor that the antiserum does not reach the 
infected tissues in the concentration in which it is present in the blood 
stream.  However, a reference to Table II shows that if a concentra- 
tion of antiserum is reached which is just on the edge of the inhibition 
zone--as was the case in the above mentioned patient after the fairly 
small dose of antiserum had been given--the concentration of the anti- 
serum can fall considerably without any marked reduction of phago- 
cytosis. 
A  third  possible  explanation  is  that  there  is  another  substance 
present in the lesion, other than the specific soluble substance, which 
has  to  be neutralized before the pneumococci can be sensitized and 
phagocyted, and that a high concentration of antiserum is necessary to 
effect this.  It is in this direction that this study is being extended. 
In the mouse experiments, no explanation can be offered as to why it 
was possible to show a marked inhibition zone in the protective action 
of Type III antiserum in  the presence of the  specific carbohydrate 
and impossible to  show a  zone in similar experiments  with  Type I 
antiserum, other than the heavier specific precipitate and the more 
marked phagocytic inhibition zone with Type III.  This very simple 
explanation of the protection inhibition zone is tentative, and much 
further work is necessary to determine the relationship between the 
antiphagocytic effect of the precipitate and the failure of the strong 
antiserum to protect in the presence of the specific soluble substance. 
CONCLUSIONS 
1.  In  vitro  phagocytic experiments with  human  blood,  antipneu- 
mococcus serum, pneumococcus specific soluble substance, and living 
virulent pneumococci show that there is a definite phagocytic inhibi- 
tion zone when strong antiserum is used. 
2.  If the antiserum is further diluted, there is a zone where phago- 
cytosis is effective.  If the serum is diluted still more, phagocytosis 
gradually falls off, as the very dilute antiserum fails to neutralize the 
specific carbohydrate, which has a specific antiphagocytic action. 702  pIIAGOCYTOSIS OF PNEUMOCOCCUS.  II 
3.  The inhibition zone is apparently caused by the specific precipi- 
tate (formed by the antiserum and the specific carbohydrate) interfer- 
ing, perhaps mechanically, with the ingestion of the pneumococci by 
the leucocytes. 
4.  The inhibition zone is better marked with Type III than with 
Type I pneumococcus. 
5. As the concentration of antiserum in the zone of effective phago- 
cytosis in vitro  does not correspond with the concentration of anti- 
serum generally used in vivo in the serum therapy of pneumonia, this 
question is discussed. 
The author wishes to express his thanks to Dr. J. M. Alston for much 
valuable assistance. 
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